Phaseline

Targets › INTS1

INTS1 (Integrator complex subunit 1): drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 3, 1 Phase 2; Infectious disease; next expected readout Mar 2028.

Component of the integrator complex, a multiprotein complex that terminates RNA polymerase II (Pol II) transcription in the promoter-proximal region of genes. The integrator complex provides a quality checkpoint during transcription elongation by driving premature transcription termination of transcripts that are unfavorably configured for transcriptional elongation: the complex terminates transcription by (1)…. (UniProt, Q8N201)

Open in Phaseline: the race on INTS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gilead SciencesIslatravir
Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor
RT, IN, POLB, INTS1, INTS8Phase 3HIV-1-Infection; HIV-1-infection; HIV-1 InfectionMar 2028

Conditions

HIV-1-Infection (1) HIV-1-infection (1) HIV-1 Infection (1)

Modalities

small molecule (1)

Companies

Gilead Sciences (1)

Related targets

RT (1) IN (1) POLB (1) INTS8 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.